Total
0
Shares
Market Herald logo

Find out more about this capital raise

Be the first with the news that moves the market
  • MYND Life Sciences (MYND) has entered into a non-brokered private placement offering of debenture units with an institutional investor
  • The company will issue up to $3,000,000 of debenture units
  • The funding will enable the company to accelerate the commercialization of its diagnostic biomarker division
  • The company's mission is to develop a pharmaceutical treatment for depression utilizing compounds found in psychedelics
  • MYND Life Sciences Inc. (MYND) opened trading at C$0.90 per share

MYND Life Sciences (MYND) entered into a non-brokered private placement offering of debenture units with an institutional investor.

The company will issue up to $3,000,000 of debenture units.

MYND Life Sciences CEO, Dr. Lyle Oberg commented on the impact of the financing.

"We are incredibly pleased to add a strategic institutional investor, who has been very active in deploying capital in novel psychedelic drug development companies, to participate in this round of financing, joining our broader investor base in advancing our novel drug discovery platform.

This capital will enable the company to accelerate the commercialization of its diagnostic biomarker division in addition to helping advance MYND's various clinical trials which are expected to commence in Q4 of this year".

The company will use the proceeds of the offering to advance its novel drug discovery platform and to commercialize its diagnostic business unit.

MYND Life Sciences is advancing medicines based on neuro-anti-inflammatory substances through rigorous science with an initial focus on major depressive disorder. The company's mission is to further research linking depression and inflammation at the genetic and cellular level to develop a pharmaceutical treatment utilizing compounds found in psychedelics.

MYND Life Sciences Inc. (MYND) opened trading at C$0.90 per share.

More From The Market Herald
Azincourt Energy (TSXV:AAZ) completes radiometric survey & updates plans for the East Preston Uranium Project

" Azincourt Energy (TSXV:AAZ) announces $7.6M private placement

Azincourt Energy (AAZ) is pleased to announce a fully-subscribed non-brokered private placement for gross proceeds of approximately $7.6 million.
Clearmind Medicine (CSE:CMND) announces closing of private placement

" Clearmind Medicine (CSE:CMND) partners with The Hebrew University

Clearmind Medicine (CMND) has established a research and development partnership with the Yissum Research Development Company.
Sabina Gold & Silver - CEO, Bruce McLeod. - The Market Herald Canada

" Sabina Gold & Silver (TSX:SBB) announces $13.75 million private placement

Sabina Gold & Silver (SBB) has secured a fully subscribed non-brokered private placement for up to C$13.75 million.
Small Pharma - CEO, Peter Rands (third from left) and the Small Pharma team. - The Market Herald Canada

" Negev Capital doubles down on Small Pharma (TSXV:DMT)

Negev Capital, a psychedelic medical intervention fund, has doubled its investment in Small Pharma (DMT).